Danaher subsidiary Cepheid has received CE-IVDR marking for its Xpert Respiratory Panel, a multiplex PCR test for 13 respiratory pathogens, with shipments to European markets starting in the coming weeks.
Cepheid, a Danaher subsidiary, received CE marking under the IVDR for its Xpert Respiratory Panel, a 13-pathogen PCR test, announced 10 November 2026. This is a regulatory approval that expands Danaher's diagnostics portfolio ahead of the European respiratory season, with shipments to CE-accepting countries in the coming weeks. The approval is real and positive, but it is a routine product clearance without revenue figures, so the price effect on a company of Danaher's size is limited.
Cepheid, a Danaher company, has secured CE-IVDR certification for its Xpert Respiratory Panel, a multiplex PCR test capable of detecting 13 common respiratory pathogens from a single swab. The diagnostic tool is designed to assist clinicians in managing respiratory infections by providing rapid results on existing GeneXpert systems, with distribution to CE-accepting markets scheduled to begin in the coming weeks.
The announcement means Cepheid's Xpert Respiratory Panel can now be sold in countries accepting the CE mark, with shipments starting in the coming weeks. However, the release gives no sales figures or financial guidance, so the monetary impact cannot be quantified from it.